Deficiency of adenosine deaminase 2 (DADA2) is an autosomal recessive autoinflammatory disorder caused by biallelic mutations in the ADA2 gene. It presents as a monogenic vasculitis with heterogeneous manifestations that often resemble small- and medium-vessel vasculitis, particularly polyarteritis nodosa (PAN)-like di...
Sofia Antolini, D. Cassandrini, S. Bindoli et al.· Reumatismo· 0 citations
In this multicentre real-world cohort of patients with GCA, including those with relapsing disease and previous biologic exposure, secukinumab was associated with high observed remission rates, progressive GC dose reduction and increasing GC-free remission.
Luca Iorio, Federica Davanzo, C. Ricordi et al.· Arthritis care & research· 0 citations
Osteoporosis weakens bones and increases the risk of fractures. Denosumab is a medication that reduces bone loss and increases bone mineral density (BMD). In this real-world study, we followed patients who received denosumab every 6 months for 10 years. We found that bone density continued to improve throughout treatme...
F. Aldegheri, Matteo Appoloni, Nicolò Passoni et al.· Archives of Osteoporosis· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.